ASELAGE STEVE — SEC Form 4 filings
SEC reporting owner CIK 1221599. 2 Form 4 filings on record with FilingPulse; latest filed 2024-06-14.
Transaction summary — filings shown
Covers all 2 filings on record, filed 2024-05-29 to 2024-06-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 2,500 shares, $16,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: purchase of 2,500 shares @ $6.40 ($16,000) in BIOCRYST PHARMACEUTICALS INC, filed 2024-05-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INC (BCRX) | Director | 2 | 1 leg · 2,500 sh · $16,000 | — | 2 |
Form 4 filings — ASELAGE STEVE
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2024-06-14 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 6,820 @ $0 · Grant/award (A): 49,933 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Purchase (P): 2,500 @ $6.40 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1221599 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →